GSK vs SNY
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 23, 2026
GSK
SNY
Investment Advisor Scores
SNY
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | SNY | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 9.7656 | 8.5911 | SNY |
| PEG Ratio | 6.1023 | 28.6272 | GSK |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | 14.6% | SNY |
| Earnings Growth | -69.5% | -91.2% | GSK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 37.4/100 | 58.7/100 | SNY |
| Profit Margin | 14.5% | 8.1% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | BUY | SNY |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
NeutralMixed signals - no dominant trend phase, RSI 63
SNY
NeutralMixed signals - no dominant trend phase, RSI 56
Fundamentals Snapshot
| Metric | GSK | SNY |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.4 | 7.9 |
| Trailing P/E | 15.8 | 21.6 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.2% |
| EPS | 3.17 | 1.90 |
| Dividend Yield | 0.04% | 0.10% |